Viromed Medical AG, a medical technology company specializing in cold plasma technology, has announced the signing of new distribution partnerships for its ViroCAP® product in six additional markets. The agreements cover Spain, Portugal, Greece, the Balkan region, Romania, and Saudi Arabia, each with a separate company, and include minimum purchase quantities, ensuring a steady revenue stream.
According to the company, these partnerships are expected to generate additional sales of at least 3,000 devices per year. ViroCAP® is a mobile medical device that uses cold atmospheric plasma for the treatment of skin conditions, targeting hospitals, private practice physicians, and surgically active medical specialists.
Uwe Perbandt, Chief Executive Officer of Viromed Medical AG, stated, "With these new distribution partners, we are opening up several attractive markets in Southern and South-Eastern Europe as well as in the Middle East. The strong interest shown by our distribution partners underlines the high demand for our cold plasma technology. The new distribution partnerships are another important step in the implementation of our dynamic growth phase. Partnerships for additional countries are in preparation and are expected to be signed within the next four to six weeks."
This expansion follows Viromed's existing international footprint, which includes an exclusive distribution agreement with South Korea's UMECO covering ten Asian countries and a distribution partnership with TriPart TITAN GmbH & Co. KG for Turkey. The new agreements further solidify Viromed's position in the global medical device market.
Viromed Medical AG, listed on the stock exchange since October 2022, focuses on the development, manufacture, and distribution of medical products, with its operating business centered on the distribution of cold plasma technology through its wholly owned subsidiary, Viromed Medical GmbH. The company has a broad customer base in the DACH region and beyond, and aims to advance the use of cold plasma technology in medicine.
The strategic expansion into these new markets is a clear indicator of Viromed's growth trajectory and the increasing adoption of cold plasma technology in medical settings. By securing distribution partners with minimum purchase commitments, Viromed ensures a predictable revenue stream and strengthens its market presence in regions with high potential for medical innovation.
